BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. major shareholders Lan Huang and Linqing Jia have jointly reported beneficial ownership of 6,048,488 ordinary shares, equal to 15% of the company’s outstanding stock. The filing aggregates shares held through British Virgin Islands entities, personal holdings, grantor retained annuity trusts, a charitable foundation, and irrevocable trusts for Dr. Huang’s children.
The percentage is calculated against 40,322,320 ordinary shares outstanding as of September 30, 2025, as disclosed in BeyondSpring’s Form 10-Q. Huang and Jia report shared voting power over all 6,048,488 shares and shared dispositive power over 1,231,804 of those shares.
BeyondSpring Inc. received an amended Schedule 13G from Decheng Capital-affiliated funds and Dr. Xiangmin Cui reporting their passive ownership of the company’s ordinary shares. The filing reflects positions as of December 31, 2025.
The group reports beneficial ownership of 3,800,702 ordinary shares by Dr. Cui, representing 9.2% of the outstanding class, held through Decheng Capital China Life Sciences USD Fund II, Fund III and Decheng Capital Global Healthcare Fund. The percentage is based on 41,122,320 ordinary shares outstanding as of November 18, 2025. The signatories certify the shares are not held for the purpose of changing or influencing control of BeyondSpring.
BeyondSpring Inc. reports an expected delay in completing the “Second Closings” of its sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. under previously signed purchase agreements.
The company had agreed to sell an aggregate 8,333,637 SEED Series A-1 Preferred Shares for approximately $35.4 million, or $4.25 per share. As part of this, Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED and Mapfil Investment Limited are scheduled to buy 1,436,327, 555,576 and 1,111,152 shares, respectively, in the Second Closings.
These Second Closings were originally to occur no later than December 15, 2025, but are now expected to be completed in the first half of 2026, with no assurance against further delays or certainty on the exact timing.
BeyondSpring Inc. entered into a Securities Purchase Agreement with Ray Beauty Group Limited for a registered offering of 800,000 ordinary shares at $2.50 per share. The transaction closed on November 21, 2025, providing gross proceeds of $2.0 million before expenses. The shares were issued off an effective shelf registration statement on Form S-3. The investor agreed to a 60-day lock-up from closing, limiting sales and derivative transactions in the shares without the company’s prior written consent, subject to specified exceptions.
BeyondSpring Inc. (BYSI) is conducting a primary offering of 800,000 ordinary shares to Ray Beauty Group Limited at $2.50 per share, raising an estimated $2 million in net proceeds after expenses. The company plans to use the cash to fund its research and development programs and for general corporate purposes, which may include clinical trial and commercial spending, working capital, debt repayment and potential acquisitions.
Shares outstanding are expected to increase from 40,322,320 to 41,122,320 as of the referenced date, modestly diluting existing holders. As of September 30, 2025, BeyondSpring reported a net tangible book value of $(0.49) per share, which would improve to $(0.43) per share on an as-adjusted basis after the offering, but investors buying in this deal face an immediate dilution of $2.93 per share. The company remains a clinical-stage biopharmaceutical developer centered on its lead oncology asset, Plinabulin, and additional preclinical immune agents.
BeyondSpring Inc. filed its Q3 2025 10‑Q, showing a year‑to‑date swing to positive net income attributable to the company of $1,131, driven by a $6,986 gain on sale of subsidiary interests tied to its SEED Therapeutics divestiture plan. From continuing operations, the company reported a year‑to‑date operating loss of $6,349 as it had no revenue, with research and development at $2,915 and general and administrative at $3,434.
Cash and cash equivalents were $12,483 at September 30, 2025. Net cash used in operating activities was $14,265 year‑to‑date, offset by $15,934 provided by investing activities, including proceeds from maturities of short‑term investments and the SEED transaction. Total assets were $29,484, total liabilities $49,294, and shareholders’ deficit widened to $(19,810), reflecting high deferred revenue balances and noncontrolling interests.
The SEED plan advanced: the first closing on February 19, 2025 sold 1,730,454 Series A‑1 shares for $7,354. A second closing is scheduled no later than December 15, 2025, and a third by December 15, 2026, which would reduce BYSI’s SEED stake to 13.62% upon completion. Shares outstanding were 40,332,320 as of September 30, 2025.
BeyondSpring Inc. (BYSI) furnished a current report to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.
BeyondSpring (BYSI): Decheng Capital–affiliated reporting persons, identified as a director, reported open-market sales of ordinary shares. On 10/16/2025, Fund III sold 85,798 shares at a weighted average price of $1.72 (prices ranged from $1.62 to $1.795). On 10/17/2025, Fund III sold 45,513 shares at a weighted average price of $1.76 (prices ranged from $1.73 to $1.80).
Following these transactions, Fund III reported 1,518,893 shares beneficially owned indirectly. Separate indirect holdings reported were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund. The sales were executed across multiple prices, with full trade breakdowns available upon request as noted in the footnotes.
BeyondSpring (BYSI) reported insider transactions by Decheng Capital–affiliated funds. Decheng Capital China Life Sciences USD Fund III, L.P. reported sales of 107,361 ordinary shares on 10/13/2025 at a weighted average price of $1.70 (range $1.69–$1.75), 28,495 shares on 10/14/2025 at $1.65 (range $1.62–$1.70), and 17,960 shares on 10/15/2025 at $1.65 (range $1.60–$1.685). Following these trades, Fund III reported 1,650,204 shares indirectly held. Other reported indirect holdings were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund.